

PHARMENABLE

unlocking innovative medicines

From academia to an AI drug discovery company



Dr Hannah Sore, Co-Founder and CEO

[PHARMENABLE.COM](https://pharmenable.com)



THE POTENTIAL FOR A NEW GENERATION OF SMALL MOLECULE THERAPEUTIC MODALITIES

Replicate the specificity of biologics in the powerful and scalable form of a **small molecule**



	SMALL MOLECULES	BIOLOGICS
Structure	✓ Small, simple	✗ Large, complex
Manufacturing	✓ Easy, cheap	✗ Challenging, costly
Stability	✓ Excellent	✗ Limited
Method of administration	✓ Oral	✗ IV
Distribution	✓ Easy	✗ Difficult
Location of action	✓ Not limited	✗ Only extracellular (20%)
Selectivity (promiscuous)	✗ Low selectivity	✓ High selectivity



CHALLENGING TARGETS NEED ACCESS TO NEW AND DIVERSE AREAS OF THE CHEMICAL SPACE

The number of possible “drug-like” small molecules

ASTRONOMIC!

10^{62}

TARGET 1



NEW CHEMICAL SPACE
REQUIRED

TARGET 4

TARGET 3

SCREENING COLLECTION 1

SCREENING COLLECTION 2

TARGET 2

Diverse 3D-shaped small
molecule collections

SCREENING COLLECTION 3



OUR VISION: UNLOCKING CHEMICAL SPACE TO DELIVER INNOVATIVE NEW MEDICINES



Dr Jelena Aleksic
(Founder, CBO)



Dr Hannah Sore
(Founder, CEO)




Dr Natalia Mateu
(Founder, CSO)



Why are you doing it?
What do you want out of it?




PHARMENABLE'S JOURNEY TO ESTABLISHING A PROPRIETARY DRUG DISCOVERY PORTFOLIO



DEVELOPING THE NEXT GENERATION SMALL MOLECULE DRUG DISCOVERY COMPANY





PHARMENABLE

unlocking innovative medicines

BUILDING A PIPELINE OF INNOVATIVE MEDICINES

EXPLORING NEW AREAS OF CHEMICAL SPACE TO UNLOCK CHALLENGING TARGETS

HIGHLY EXPERIENCED AND WORLD CLASS TEAM



PHARMENABLE.COM

hannah.sore@pharmenable.com